Millions of Americans filling generic prescriptions at the pharmacy counter may be paying more through their insurance copay than they would with a free discount card. Federal regulators have moved to ban the contractual gag clauses that kept pharmacists from sharing that information, and new research quantifies just how much the gap between copay and actual drug cost can cost patients on routine medications.
Federal gag-clause ban and the copay gap on generics
The core problem is straightforward: a patient hands over a fixed copay, say $15 or $20, for a generic drug whose actual price at the pharmacy may be far less. The difference does not go back to the patient. Instead, it can be retained by pharmacy benefit managers through a practice known as a “clawback.” Analysis from the USC Schaeffer Center found that fixed copays can exceed the market or paid price for generics, and the spread between the two is captured as revenue by middlemen in the drug supply chain.
Until recently, contractual gag clauses between insurers and pharmacies prevented pharmacists from volunteering this information. A patient could be standing at the counter overpaying and the pharmacist was contractually barred from saying so. The Centers for Medicare and Medicaid Services has explicitly warned that such clauses can block pharmacists from telling patients when a simple cash price would be cheaper than using their insurance, noting that these communication restrictions keep people in the dark about lower-cost options.
Congress and regulators have since moved to curb gag clauses in Medicare, Medicaid, and many commercial plans, aiming to align what patients pay more closely with what pharmacies actually receive. But even with the formal bans, the underlying pricing structure that made clawbacks profitable has not disappeared. Patients typically still see only a copay amount on their receipt, not the negotiated reimbursement or the pharmacy’s acquisition cost.
Researchers and policymakers have floated the idea that, once pharmacists are free to speak, more patients might opt to pay cash or use discount programs for inexpensive generics. The hypothesis that states with early gag-clause bans would see a measurable rise in cash generic claims after the federal rule took effect has not yet been tested with publicly available prescription-volume data. No aggregated claims dataset tracking that shift has surfaced in CMS releases or independent research to date. The idea is plausible on its face, but the data to confirm or reject it does not appear in the public record.
FTC and USC findings on PBM spread pricing
The Federal Trade Commission added new detail to this picture with its second interim staff report on prescription drug middlemen released in January 2025. In that report, the agency described how large pharmacy benefit managers use spread pricing to generate revenue, documenting cases in which PBMs charged health plans substantially more than they reimbursed pharmacies for the same prescription. According to the FTC’s own press materials, staff identified significant markups on certain specialty generics and estimated sizable spread-pricing income flowing to the intermediaries.
Spread pricing occurs when a PBM bills an employer or insurer one price for a drug and pays the dispensing pharmacy a lower amount, pocketing the difference. When that dynamic combines with a fixed copay structure, patients can end up paying more out of pocket than the pharmacy actually received for the medication. In extreme cases, the patient’s copay can exceed the total reimbursement paid to the pharmacy, creating a direct transfer from the patient to the PBM.
The USC Schaeffer analysis and the FTC findings describe the same basic mechanism from different angles. USC researchers used claims data to document copay clawbacks on common generics, showing that the gap between what patients pay and what drugs actually cost is not an occasional glitch but a structural feature of the current benefit design. The FTC report broadened the lens to examine how PBMs profit from that structure across specialty generics, suggesting that spread pricing and opaque contracts can inflate costs for health plans even when patients never see the underlying numbers.
What patients still cannot easily verify
Several gaps in the evidence leave patients without clear tools to act on this information. CMS has not published a comprehensive, drug-by-drug comparison of typical copays, negotiated reimbursements, and pharmacy acquisition costs that would allow consumers to see where clawbacks are most likely. The FTC’s interim report, while detailed on PBM business practices, focuses primarily on plan-level and system-wide effects rather than on the everyday choices facing someone filling a $5 generic prescription.
Even in the post–gag clause environment, much depends on what pharmacists know and feel comfortable sharing. Pharmacies may not have real-time visibility into all of the PBM’s pricing decisions, and staff working under tight time pressure may default to processing the insurance claim rather than pausing to check whether a cash price or discount card would be cheaper. Contract terms can also remain complex enough that pharmacists are unsure how much they can say without risking disputes with payers.
For now, patients who want to avoid overpaying must navigate this opacity themselves. That can mean asking the pharmacist to run the prescription both with insurance and as a cash sale, comparing prices from widely available discount programs, and revisiting those comparisons whenever a plan year or formulary changes. The regulatory shift away from gag clauses has removed a formal barrier to these conversations, but it has not yet delivered the transparent, standardized price information that would make lower-cost choices obvious at the counter.
